London, United Kingdom, April 27, 2022- Leading specialist market access consultancy Partners4Access analyst’s have been awarded ‘Highly Commended’’ Analyst Team of the Year 2022 by
By Fisentzos Stylianou, PhD Contact: Fstylianou@partners4access.com One of the main healthcare challenges raised by the European Medicines Agency’s (EMA) network strategy to 2025 is the
By Chloe Sheppard, Associate Consultant Contact: csheppard@partners4access.com A major milestone in the creation of pan-European joint health technology assessment (HTA) was reached in January this
By Fisentzos Stylianou, PhD Contact: Fstylianou@partners4access.com In November 2021, Novartis’ Adakveo (crizanlizumab) became the first treatment for sickle cell disease (SCD) to be made available
By Andrea Bernardini, Senior Analyst Email: abernardini@partners4access.com AIFA has approved reimbursement of the orphan drug Evrysdi (risdiplam) by Roche, the first at-home oral treatment for Spinal
By Andrea Bernardini, Senior Analyst Email: abernardini@partners4access.com Intensifying pressure to implement cost savings due to COVID induced economic downturn and the current ruling coalition, seem
By Andrea Bernardini, Senior Analyst Email: abernardini@partners4access.com The latest approved Budget Law for the three-year period 2022-2024 is quite extensive and covers the whole planned spending
By Andrea Bernardini, Analyst & Akshay Kumar, Partner Email: abernardini@partners4access.com akumar@partners4access.com On the 12th of February the Orphan Drugs Observatory and the Italian Society of
Leading specialist market access consultancy Partners4Access (P4A) is to host a free webinar to share insights on key 2021 trends in market access for pharma/biotech
